Compounds containing these compounds and treatments for various diseases including the management of these compounds. Claim 1: a compound according to formula (1), wherein R1,R2,R3,R⁴ and R⁵ are independently selected from each other from H, C₁₋₆ alkyl,C₂₋₆ alkenyl,1. C 83228331 asphalt；C₁₋₆ alkoxy,a. Cyanogen and halogen, of which c83231 and 832626；C₂₋₆ alkenyl and C₂₋₆ alkynyl are optionally substituted with one or more substituents independently selected from chlorine and fluorine； R⁶ is selected from C₁₋₆ alkyl,C₂₋₆ alkenyl,C₂₋₆ alkynyl and C₁₋₆ alkoxy,where said C₁₋₆ alkyl,C₂₋₆ alkenyl and C₂₋₆ alkynyl are optionally substituted with one or more substituents independently selected from hydroxy, C₁₋₆ alkoxy and fluorine； A⁷ is C-R⁷ or N, A⁸ is C-R⁸ or N and A⁹ is C-R⁹ or N, provided that at least one of A⁷,a. A8312 and / or a8313 are n, but not more than two of a8311；A8312 and a8313 Sean n； r8311811；R8322,R8313,R83041 and R1 are independent from h, acquilo c83218c83312626,C₂₋₆ alkenyl,1. C 83228331 asphalt；C₁₋₆ alkoxy,Cyanide, Nr.1C₁₋₆ alkylsulfonyl,halogen and OR¹⁴,where said C₁₋₆ alkyl,C₂₋₆ alkenyl,C₂₋₆ alkynyl or C₁₋₆ alkoxy is optionally substituted with one or more substituents selected from chlorine, fluorine, C₁₋₆ alkoxy,cyano and NR¹²R¹³；R2 and R1 3 independently represent hydrogen, hydrocarbon c8321c8331；C₂₋₆ alkenyl and C₂₋₆ alkynyl；R83088 represents the remaining part of a single ring saturated ring, in which there are 4-6 ring atoms, one of which is O and the rest is C； or r83013 and r1830404 may be interconnected to form the remaining equation of 1, 2 or 3； and the pharmaceutically acceptable salts thereof； The condition is that the compound is another [(s)] L - [5 - (2,2,2-trifluoro-tetraethyl) - pyridine-2-il] - ethyl} - acid amide (1s, 2S) - 2-phenyl-cyclopropane； [(s)] 1 - [5 - (2,2-trifluoro-tetraethyl) - pyridine-2-1] - acetyl ammonia (1s, 2S) - 2-chloro-propyl-fluoro-4；{ fnhobo STD fs48} 1 - [5 - (2,2,2-trifluoro-tetraethyl) - pyridine-2
